RXRX * Stock Overview

Operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. More details

RXRX * fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 20.9% per year

Risk Analysis

Earnings are forecast to decline by an average of 3.9% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

Capture your thoughts, links and company narrative

Recursion Pharmaceuticals, Inc. Competitors

ADMA Biologics

NasdaqGM:ADMA

US$3.8b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.8b

Xiamen Amoytop Biotech

SHSE:688278

CN¥32.6b

Genomma Lab Internacional. de

BMV:LAB B

Mex$26.6b

Price History & Performance

Summary of share price highs, lows and changes for Recursion Pharmaceuticals
Historical stock prices
Current Share Price	US$219.00
52 Week High	US$219.00
52 Week Low	US$200.00
Beta	0.86
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	9.50%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	RXRX *	MX Biotechs	MX Market
7D	n/a	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how RXRX * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how RXRX * performed against the MX Market.

Price Volatility

Is RXRX *'s price volatile compared to industry and market?
RXRX * volatility
RXRX * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: RXRX *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine RXRX *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	500	Chris Gibson	www.recursion.com

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer.

Recursion Pharmaceuticals, Inc. Fundamentals Summary

How do Recursion Pharmaceuticals's earnings and revenue compare to its market cap?
RXRX * fundamental statistics
Market cap	Mex$84.13b
Earnings (TTM)	-Mex$7.65b
Revenue (TTM)	Mex$1.32b

64.4x

P/S Ratio

-11.1x

P/E Ratio

Is RXRX * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RXRX * income statement (TTM)
Revenue	US$65.18m
Cost of Revenue	US$327.89m
Gross Profit	-US$262.71m
Other Expenses	US$115.04m
Earnings	-US$377.75m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.96
Gross Margin	-403.03%
Net Profit Margin	-579.51%
Debt/Equity Ratio	0.2%

How did RXRX * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/18 16:20
End of Day Share Price	2025/02/18 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recursion Pharmaceuticals, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gal Munda	Berenberg
Gaurav Goparaju	Berenberg
Alec Stranahan	BofA Global Research